



(12) Translation of
European patent specification

(11) NO/EP 4061344 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 31/05 (2006.01)

A61P 25/08 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.07.01
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.05.29
(86)	European Application Nr.	20815902.0
(86)	European Filing Date	2020.11.18
(87)	The European Application's Publication Date	2022.09.28
(30)	Priority	2019.11.21, GB, 201916974
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	GW Research Limited, Sovereign House Vision Park Chivers Way Histon, Cambridge, Cambridgeshire CB24 9BZ, Storbritannia
(72)	Inventor	GUY, Geoffrey, GW Pharma Limited Sovereign House, Vision Park Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ, Storbritannia KNAPPERTZ, Volker, GW Pharma Limited Sovereign House, Vision Park Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ, Storbritannia WHALLEY, Benjamin, GW Pharma Limited Sovereign House, Vision Park Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ, Storbritannia WOOLLEY-ROBERTS, Marie, GW Pharma Limited Sovereign House, Vision Park Chivers Way, Histon, Cambridge Cambridgeshire CB24 9BZ, Storbritannia
(74)	Agent or Attorney	Nordic Patent Service A/S, Bredgade 30, 1260 KØBENHAVN K, Danmark

(54) Title **6-HYDROXY CANNABIDIOL FOR USE AS A MEDICAMENT**

(56) References
Cited:

US-B1- 6 630 507

GASTON TYLER E ET AL: "Cannabis for the Treatment of Epilepsy: an Update", CURRENT
NEUROLOGY AND NEUROSCIENCE REPORTS, PHILADELPHIA, PA. : CURRENT SCIENCE
INC, US, vol. 18, no. 11, 8 September 2018 (2018-09-08), pages 1-9, XP036608791, ISSN:
1528-4042, DOI: 10.1007/S11910-018-0882-Y [retrieved on 2018-09-08]

ISTVÁN UJVÁRY ET AL: "Human Metabolites of Cannabidiol: A Review on Their Formation,
Biological Activity, and Relevance in Therapy", CANNABIS AND CANNABINOID RESEARCH,
vol. 1, no. 1, 1 December 2016 (2016-12-01), pages 90-101, XP55765903, ISSN: 2378-8763,
DOI: 10.1089/can.2015.0012

LANDER N ET AL: "TOTAL SYNTHESSES OF CANNABIDIOL AND DETLA1-
TETRAHYDROCANNABINOL METABOLITES", JOURNAL OF THE CHEMICAL SOCIETY,
PERKIN TRANSACTIONS 1, ROYAL SOCIETY OF CHEMISTRY, CAMBRIDGE, UK, vol. 1, 1
January 1976 (1976-01-01), pages 8-16, XP001073667, ISSN: 0300-922X, DOI:
10.1039/P19760000008

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. 6-hydroksycannabidiol (6-OH CBD) for anvendelse som et medikament.
2. 6-OH CBD for anvendelse ifølge krav 1, hvori 6-OH CBD er i form av en syntetisk
5 forbindelse.
3. 6-OH CBD for anvendelse ifølge krav 1, hvori 6-OH CBD er i form av en ren eller isolert forbindelse.
- 10 4. 6-OH CBD for anvendelse ifølge et hvilket som helst av de foregående kravene, hvori dosen av 6-OH CBD er større enn 100 mg/kg/dag.
5. 6-OH CBD for anvendelse ifølge et hvilket som helst av kravene 1 til 3, hvori dosen av 6-OH CBD er mindre enn 100 mg/kg/dag.
- 15 6. Sammensetning for anvendelse som et medikament omfattende 6-hydroksycannabidiol (6-OH CBD) og én eller flere farmasøytisk akseptable eksipienser.
7. 6-hydroksycannabidiol (6-OH CBD) for anvendelse i behandlingen av epilepsi.
- 20 8. 6-OH CBD for anvendelse ifølge krav 7, hvori den behandlede epilepsien er i et pattedyr.
9. 6-OH CBD for anvendelse ifølge krav 8, hvori pattedyret er et menneske.
- 25 10. 6-OH CBD for anvendelse ifølge krav 8, hvori pattedyret er en hund.